Biological
Sinovac COVID-19 vaccine clinical trials
Also written CoronaVac.
- studies test it
- 25
- open now
- 0
- in phase 3
- 6
- first study started
- 2020
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2021 (20)
| Year | Studies |
|---|---|
| 2020 | 3 |
| 2021 | 20 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
- Phase 3
- 6
- Phase 4
- 14
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 21
Who runs them
Industry 9 · Other 16
Sinovac Research and Development Co., Ltd. (6) · The University of Hong Kong (2) · Butantan Institute (2) · Sinovac Life Sciences Co., Ltd. (2) · D'Or Institute for Research and Education (2) · Jiangsu Province Centers for Disease Control and Prevention (1) · Health Institutes of Turkey (1) · University of Sao Paulo General Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses sinovac COVID-19 vaccine is read from its arms, and is right about nine times in ten.
Testing it · 25
- Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)CompletedPhase 4The University of Hong KongNCT05057169Written as CoronaVac
- Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 VaccineCompletedPhase 4Jiangsu Province Centers for Disease Control and PreventionNCT05303584Written as CoronaVac
- Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and AboveCompletedPhase 3Sinovac Research and Development Co., Ltd.NCT05381350Written as COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)
- Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)CompletedPhase 3Health Institutes of TurkeyNCT04582344Written as CoronaVac
- COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDSCompletedPhase 4University of Sao Paulo General HospitalNCT04754698Written as CoronaVac
- Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare ProfessionalsCompletedPhase 3Butantan InstituteNCT04456595Written as Adsorbed COVID-19 (inactivated) Vaccine
- An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) VaccineCompletedPhase 4Butantan InstituteNCT04747821Written as Adsorbed COVID-19 (Inactivated) Vaccine
- Covid-19 Vaccination in Adolescents and ChildrenActive, not recruitingPhase 2The University of Hong KongNCT04800133Written as CoronaVac
- Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 YearsActive, not recruitingPhase 4Sinovac Research and Development Co., Ltd.NCT05112913Written as Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2
- Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 YearsCompletedPhase 3Sinovac Research and Development Co., Ltd.NCT05137418Written as COVID-19 Vaccine,Inactivated
- Antibody Response to COVID-19 Vaccines in Liver Disease PatientsCompletedPhase 4Humanity & Health Medical Group LimitedNCT04775069Written as CoronaVac
- Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in AdultsCompletedPhase 4Sinovac Research and Development Co., Ltd.NCT04911790Written as Experimental Group
- Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and AdolescentsCompletedPhase 4Sinovac Life Sciences Co., Ltd.NCT04992208Written as Experimental Group
- Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and AdolescentsCompletedPhase 2Sinovac Life Sciences Co., Ltd.NCT04884685Written as SARS-CoV-2 Inactivated Vaccine
- Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in AdultsCompletedPhase 3Pontificia Universidad Catolica de ChileNCT04651790Written as SARS-CoV-2 inactivated vaccine
- Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 VaccinesCompletedPhase 3Institut Pasteur de TunisNCT05668065Written as CoronaVac/CoronaVac
- SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer PatientsCompletedNot applicableNational Cancer Institute, ThailandNCT05313074Written as CoronaVac vaccine
- Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy AdultsCompletedPhase 4Sinovac Research and Development Co., Ltd.NCT04894227Written as Inactivated SARS-CoV-2 Vaccine (Vero cell）
- Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant RecipientsStatus unknownPhase 4Hospital do Rim e HipertensãoNCT04801667Written as Coronavac
- Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19Status unknownPhase 4Sinovac Biotech Co., LtdNCT05079217Written as High-dosage SARS-CoV-2 vaccine
See all 25 studies that test sinovac COVID-19 vaccine →
As the comparator · 15 — what is tested is compared with sinovac COVID-19 vaccine
- Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy AdolescentCompletedPhase 2Health Institutes of TurkeyNCT05230940Written as CoronaVac
- Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine BoosterCompletedPhase 1Argorna Pharmaceuticals Co., LTDNCT05897190Written as CoronaVac®
- Phase 3 Booster Vaccination Against COVID-19CompletedPhase 3Health Institutes of TurkeyNCT05077176Written as CoronaVac
- Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac VaccineCompletedPhase 3Health Institutes of TurkeyNCT04942405Written as CoronaVac
- Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in ChileCompletedPhase 2Pontificia Universidad Catolica de ChileNCT05593042Written as CoronaVac®
- Booster Vaccination Against COVID-19CompletedPhase 2Health Institutes of TurkeyNCT04979949Written as CoronaVac
- Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in AdultsCompletedPhase 3Clover Biopharmaceuticals AUS Pty LtdNCT05188677Written as CoronaVac Vaccine
- The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001Active, not recruitingEarly Phase 1Guangzhou Patronus Biotech Co., Ltd.NCT05928455Written as CoronaVac
- Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018CompletedPhase 1PT Bio FarmaNCT05228613Written as SARS-CoV-2 inactivated vaccine
- Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in IslamabadStatus unknownPhase 3AIM Vaccine Co., Ltd.NCT05428592Written as CoronaVac®
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy PeopleStatus unknownPhase 3Sinocelltech Ltd.NCT05683561Written as CoronaVac
- Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351Status unknownEarly Phase 1Livzon Pharmaceutical Group Inc.NCT05583357Written as CoronaVac
- Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly AdultsCompletedPhase 4Jiangsu Province Centers for Disease Control and PreventionNCT04952727Written as Inactive SARS-CoV-2 vaccine (Vero cell)
- Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant VaccineCompletedPhase 1PT Bio FarmaNCT05067894Written as SARS-CoV-2 Inactivated Vaccine
- Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)CompletedPhase 4Jiangsu Province Centers for Disease Control and PreventionNCT04892459Written as Inactive SARS-CoV-2 vaccine (Vero cell)
Codes
What other systems call sinovac COVID-19 vaccine · ClinicalTrials.gg INT001828
- MeSH (NLM) C000722216sinovac COVID-19 vaccineOne source NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722216 | sinovac COVID-19 vaccine | One source NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.